内镜下局部注射新型培普利霉素给药制剂治疗浅表性食管癌的初步研究
Endoscopic local injection of a new drug-delivery format of peplomycin for superficial esophageal cancer: a pilot study.
作者信息
Hagiwara A, Takahashi T, Kojima O, Kitamura K, Sakakura C, Shoubayashi S, Osaki K, Iwamoto A, Lee M, Fujita K
机构信息
First Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
出版信息
Gastroenterology. 1993 Apr;104(4):1037-43. doi: 10.1016/0016-5085(93)90271-d.
BACKGROUND
A new drug-delivery format comprising activated carbon particles adsorbing peplomycin (PEP-CH) was developed for the treatment of superficial esophageal cancer.
METHODS
The drug distribution was measured in rats that received subcutaneous injections of PEP-CH or peplomycin aqueous solution. In 6 patients with superficial esophageal cancer, peplomycin as PEP-CH, 5-10 mg once a week for 4-10 weeks (total, 40-100 mg/patient) was injected endoscopically into primary lesions.
RESULTS
Rats given PEP-CH had significantly higher peplomycin levels in the regional lymph nodes and the injection site than rats given aqueous solution. Five patients have survived to the present or died without cancer after 27-72 months. The remaining patient has survived without cancer for 8 months after a second course of PEP-CH against recurrence.
CONCLUSIONS
PEP-CH therapy seems to have a good therapeutic effect on superficial esophageal cancer, although the present clinical study may have been biased by patient selection.
背景
开发了一种由吸附培普利欧霉素的活性炭颗粒组成的新型给药形式（PEP-CH）用于治疗浅表性食管癌。
方法
在接受皮下注射PEP-CH或培普利欧霉素水溶液的大鼠中测量药物分布。在6例浅表性食管癌患者中，将作为PEP-CH的培普利欧霉素，每周一次5-10mg，共4-10周（总量，40-100mg/患者）通过内镜注射到原发性病变中。
结果
给予PEP-CH的大鼠区域淋巴结和注射部位的培普利欧霉素水平显著高于给予水溶液的大鼠。5例患者在27-72个月后存活至今或死于非癌症原因。其余1例患者在接受第二疗程的PEP-CH抗复发治疗后无癌存活8个月。
结论
PEP-CH疗法似乎对浅表性食管癌有良好的治疗效果，尽管目前的临床研究可能因患者选择而存在偏差。
Zotero 插件